MimiVax and UI Pharmaceuticals Achieve Milestone in SurVaxM Production for Glioblastoma Treatment | PR Newswire [Video]

• SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facility
• UI Pharmaceuticals is looking forward to supporting the need for larger clinical and commercial lots
• MimiVax is utilizing SurVaxM in a Randomized Phase 2b clinical trial of glioblastoma

, /PRNewswire/ — MimiVax, Inc. and UI Pharmaceuticals are proud to announce the successful clinical manufacture of SurVaxM, a novel immunotherapeutic vaccine targeting Glioblastoma (GBM), at UIP’s recently qualified $26M sterile manufacturing facility. This collaboration combines MimiVax’s innovative research with UIP’s expertise in formulation development and sterile production, accelerating the path to potentially transformative therapies for patients.

SurVaxM by MimiVax is the first drug product to be produced in UI Pharmaceuticals new facility

At MimiVax, our mission is to disrupt cancer. We are dedicated to improving survival and sending hope to cancer patients and this milestone achievement in SurVaxM production brings us one step closer to realizing that mission. Both organizations look forward to the potential impact of …